IBEX Technologies Inc. company develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX also provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where sales revenues are split evenly. The publicly-traded company, founded in 1972, is led by CEO Paul Baehr.

Arnet Pharmaceutical manufactures private-label nutritional supplements. Arnet Pharmaceutical Corp. products range from daily vitamins and herbal extracts to minerals and amino acids. The company's capabilities include making tablet, capsule, powder, and chewable products. As a contract manufacturer, Arnet will work from customer-provided formulations or formulate products themselves. It also produces blended products such as Osteoporex, a calcium blend to address osteoporosis, and Gluthatione, an antioxidant supplement to increases energy and reduces stress. Founded in 1972, Arnet's customers span across more than 50 countries.

Advanced Life Sciences Holdings, Inc. company was founded in 1999 and is headquartered in Woodridge, Illinois. Advanced Life Sciences Holdings, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and respiratory disease. The Company has assembled a pipeline of clinical and preclinical product candidates. In September 2008, the Company entered into a development and commercialization agreement with Wyeth for cethromycin in the Asia Pacific region excluding Japan. Advanced Life Sciences Holdings, Inc. has a worldwide license (excluding Japan) from Abbott Laboratories (Abbott) to develop and commercialize cethromycin, once-a-day antibiotic for the treatment of respiratory tract infections. On September 30, 2008, the Company submitted a new drug application for the use of cethromycin in community acquired pneumonia.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

AstraZeneca Czech Republic is a subsidiary of the international pharmaceutical behemoth known as AstraZeneca. It markets products such as heartburn reliever Nexium, local anesthetic Xylocaine, and endometriosis treatment Zoladex in the Czech Republic. It also conducts clinical trials on potential drug candidates in other parts of Central and Eastern Europe, such as Bulgaria, Hungary, Poland, Romania, and Slovenia. It focuses its research efforts primarily on the medical fields of gastroenterology, gynecology, and oncology, as well as bone and joint, cardiovascular, infectious, and respiratory diseases.

The Quigley Corporation company was founded in 1989 and is headquartered in Doylestown, Pennsylvania. The Quigley Corporation is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products which comprise the Cold Remedy and Contract Manufacturing segments. The Company is also involved in the research and development of potential natural base health products, including, but not limited to, prescription medicines along with supplements and cosmeceuticals for human and veterinary use, which comprise the Ethical Pharmaceutical segment. Cold-Eeze is one of the Company’s primary cold remedy over the counter (OTC) products. The Cold Remedy segment, where Cold-Eeze is represented, is reviewed regularly to realize any new consumer opportunities in flavor, convenience and packaging to help improve market share for the Cold-Eeze product. The Company’s customers include a range of large wholesalers, mass merchandisers, and multi-outlet pharmacy chains.

Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts. Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology.

Endocyte, Inc. company was founded in 1996 and is based in West Lafayette, Indiana. Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers.

Isagenix International company develops and manufactures a range of health and wellness products from nutritional and dietary supplements to skin care products and systems. Isagenix's line of "Nutritional Cleansing" products help improve health by accelerating the removal of impurities from the body and by replacing the impurities with nutrients to revive health. The company also offers dietary supplements to help customers lose weight and increase energy. A network marketing enterprise, Isagenix provides the products and sales support services to its international network of associates, relying on its associates to sell the products and recruit new associates.

Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.